Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph Positive Chronic Myeloid Leukemia In Chronic Phase Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR ABL RQ PCR

Authors
Publication date
1 December 2010
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Supporting member

    Queen's University Belfast Research Portal

    redirect
    oaioai:pure.qub.ac.uk/portal:publ...
    Last time updated on 09/05/2013